Age-period-cohort analysis of primary bone cancer incidence rates in the United States (1976-2005)

Cancer Epidemiology Biomarkers and Prevention

Volumn 20, Issue 8, 2011, Pages 1770-1777

  Anfinsen, Kristin P ^a   Devesa, Susan S ^e   Bray, Freddie ^d,f   Troisi, Rebecca ^e   Jonasdottir, Thora J ^a   Bruland, Oyvind S ^b,c   Grotmol, Tom ^a,d  

^a NORWEGIAN UNIVERSITY OF LIFE SCIENCES   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d Cancer Registry of Norway ^*  (Norway)

^e NATIONAL CANCER INSTITUTE   (United States)

^f INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; ORAL CONTRACEPTIVE AGENT; RADIOISOTOPE;

ADULT; AGED; ARTICLE; BONE CANCER; CANCER INCIDENCE; CANCER PATIENT; CANCER RISK; CARTILAGE CELL; CELL PROLIFERATION; CHONDROSARCOMA; COHORT ANALYSIS; EWING SARCOMA; FEMALE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; MENOPAUSE; OSTEOSARCOMA; PRIMARY TUMOR; PRIORITY JOURNAL; UNITED STATES;

ADULT; AGE FACTORS; AGED; BONE NEOPLASMS; COHORT STUDIES; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; UNITED STATES; YOUNG ADULT;

EID: 79961233096     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-11-0136     Document Type: Article

References (40)

1. Bacci G, Rocca M, Salone M, Balladelli A, Ferrari S, Palmerini E, et al. High grade osteosarcoma of the extremities with lung metastases at presentation: treatment with neoadjuvant chemotherapy and simultaneous resection of primary and metastatic lesions. J Surg Oncol 2008;98:415-20.
2. Brandal P, Bjerkehagen B, Bruland OS, Skjeldal S, Bogsrud TV, Hall KS. Synchronous and metachronous skeletal osteosarcomas: the Norwegian Radium Hospital experience. Acta Oncol 2009;48:1165-72.
3. Bruland OS, Pihl A. On the current management of osteosarcoma. A critical evaluation and a proposal for a modified treatment strategy. Eur J Cancer 1997;33:1725-31. (Pubitemid 28129196)
4. Ferrari S, Smeland S, Mercuri M, Bertoni F, Longhi A, Ruggieri P, et al. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol 2005;23:8845-52. (Pubitemid 46211531)
5. Hawkins MM, Wilson LM, Burton HS, Potok MH, Winter DL, Marsden HB, et al. Radiotherapy, alkylating agents, and risk of bone cancer after childhood cancer. J Natl Cancer Inst 1996;88:270-8. (Pubitemid 26073371)
6. Miller RW, Boice JD Jr, Curtis RE. Bone cancer. In: Schottenfeld D, Fraumeni JF Jr, editors. Cancer epidemiology and prevention, 3rd ed. Oxford University Press, New York; 2006. p. 946-58.
7. Wong FL, Boice JD Jr, Abramson DH, Tarone RE, Kleinerman RA, Stovall M, et al. Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. JAMA 1997;278:1262-7. (Pubitemid 27435614)
8. Brenton DP, Isenberg DA, Bertram J. Osteosarcoma complicating familial Paget's disease. Postgrad Med J 1980;56:238-43. (Pubitemid 10147308)
9. Frassica FJ, Sim FH, Frassica DA, Wold LE. Survival and management considerations in postirradiation osteosarcoma and Paget's osteosarcoma. Clin Orthop Relat Res 1991;120-7. Review.
10. Moppett J, Oakhill A, Duncan AW. Second malignancies in children: the usual suspects? Eur J Radiol 2001;38:235-48.
11. Ottaviani G, Jaffe N. The etiology of osteosarcoma. Cancer Treat Res 2010;152:15-32.
12. Troisi R, Masters MN, Joshipura K, Douglass C, Cole BF, Hoover RN. Perinatal factors, growth and development, and osteosarcoma risk. Br J Cancer 2006;95:1603-7. (Pubitemid 44863368)
13. Damron TA, Ward WG, Stewart A. Osteosarcoma, chondrosarcoma, and Ewing's sarcoma: National Cancer Data Base Report. Clin Orthop Relat Res 2007;459:40-7. (Pubitemid 46878192)
14. Polednak AP. Primary bone cancer incidence in black and white residents of New York State. Cancer 1985;55:2883-8. (Pubitemid 15008333)
15. Jawad MU, Cheung MC, Min ES, Schneiderbauer MM, Koniaris LG, Scully SP. Ewing sarcoma demonstrates racial disparities in incidence-related and sex-related differences in outcome: an analysis of 1631 cases from the SEER database, 1973-2005. Cancer 2009;115:3526-36.
16. Delattre O, Zucman J, Plougastel B, Desmaze C, Melot T, Peter M, et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 1992;359:162-5.
17. Bovée JV, Hogendoorn PC, Wunder JS, Alman BA. Cartilage tumours and bone development: molecular pathology and possible therapeutic targets. Nat Rev Cancer 2010;10:481-8.
18. Surveillance, Epidemiology, and End Results (SEER) Program (www. seer.cancer.gov) SEER*Stat Database: Incidence - SEER 9 Regs Research Data, Nov 2007 Sub (1973-2005) ⟨Single Ages to 85+, Katrina/Rita Population Adjustment⟩ - Linked To County Attributes - Total U.S., 1969-2005 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2008, based on the November 2007 submission.
19. World Health Organization. International classification of diseases for oncology, 3rd ed. Geneva, Switzerland: World Health Organization; 2000.
20. Devesa SS, Donaldson J, Fears T. Graphical presentation of trends in rates. Am J Epidemiol 1995;141:300-4.
21. Holford TR. The estimation of age, period and cohort effects for vital rates. Biometrics 1983;39:311-24.
22. Holford TR. Age-period-cohort analysis. In: Encyclopedia of Biostatistics. Chichester: John Wiley & Sons; 1998. p. 82-99.
23. Holford TR. Analysing the temporal effects of age, period and cohort. Stat Methods Med Res 1992;1:317-37.
24. R development Core Team. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2008.
25. Stata Statistical Software, College Station. StataCorp, editor. Texas, StataCorp LP; 2009.
26. Mirabello L, Troisi RJ, Savage SA. International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons. Int J Cancer 2009;125:229-34.
27. Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer 2009;115:1531-43.
28. Giuffrida AY, Burgueno JE, Koniaris LG, Gutierrez JC, Duncan R, Scully SP. Chondrosarcoma in the United States (1973 to 2003): an analysis of 2890 cases from the SEER database. J Bone Joint Surg Am 2009;91:1063-72.
29. Bergström R, Adami HO, Möhner M, Zatonski W, Storm H, Ekbom A, et al. Increase in testicular cancer incidence in six European countries: a birth cohort phenomenon. J Natl Cancer Inst 1996;88:727-33.
30. Tretli S, Gaard M. Lifestyle changes during adolescence and risk of breast cancer: an ecologic study of the effect of World War II in Norway. Cancer Causes Control 1996;7:507-12. (Pubitemid 26306783)
31. Loutit JF, Corp MJ, Ardran GM. Radiographic features of bone in several strains of laboratory mice and of their tumours induced by bone-seeking radionuclides. J Anat 1976;122:357-75.
32. Mosher WD, Martinez GM, Chandra A, Abma JC, Willson SJ. Use of contraception and use of family planning services in the United States: 1982-2002. Adv Data 2004;1-36.
33. Brett KM, Madans JH. Use of postmenopausal hormone replacement therapy: estimates from a nationally representative cohort study. Am J Epidemiol 1997;145:536-45. (Pubitemid 27111222)
34. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33. (Pubitemid 34761611)
35. Bovée JV, Cleton-Jansen AM, Taminiau AH, Hogendoorn PC. Emerging pathways in the development of chondrosarcoma of bone and implications for targeted treatment. Lancet Oncol 2005;6:599-607. (Pubitemid 41051938) Review.
36. Rodd C, Jourdain N, Alini M. Action of estradiol on epiphyseal growth plate chondrocytes. Calcif Tissue Int 2004;75:214-24. (Pubitemid 39331650)
37. Grifone TJ, Haupt HM, Podolski V, Brooks JJ. Immunohistochemical expression of estrogen receptors in chondrosarcomas and enchondromas. Int J Surg Pathol 2008;16:31-7.
38. Cleton-Jansen AM, van Beerendonk HM, Baelde HJ, Bovée JV, Karperien M, Hogendoorn PC. Estrogen signaling is active in cartilaginous tumors: implications for antiestrogen therapy as treatment option of metastasized or irresectable chondrosarcoma. Clin Cancer Res 2005;11:8028-35. (Pubitemid 41698744)
39. Dohi O, Hatori M, Suzuki T, Ono K, Hosaka M, Akahira J, et al. Sex steroid receptors expression and hormone-induced cell proliferation in human osteosarcoma. Cancer Sci 2008;99:518-23. (Pubitemid 351228568)
40. Salvatori L, Caporuscio F, Coroniti G, Starace G, Frati L, Russo MA, et al. Down-regulation of epidermal growth factor receptor induced by estrogens and phytoestrogens promotes the differentiation of U2OS human osteosarcoma cells. Cell Physiol 2009;220:35-44.